Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

ErbB2 overexpression in an ovarian cancer cell line confers sensitivity to the HSP90 inhibitor geldanamycin.

Smith V, Hobbs S, Court W, Eccles S, Workman P, Kelland LR.

Anticancer Res. 2002 Jul-Aug;22(4):1993-9.

PMID:
12174876
2.
3.

Sensitivity of mature Erbb2 to geldanamycin is conferred by its kinase domain and is mediated by the chaperone protein Hsp90.

Xu W, Mimnaugh E, Rosser MF, Nicchitta C, Marcu M, Yarden Y, Neckers L.

J Biol Chem. 2001 Feb 2;276(5):3702-8.

4.

Expression of epidermal growth factor receptor or ErbB3 facilitates geldanamycin-induced down-regulation of ErbB2.

Pedersen NM, Breen K, Rødland MS, Haslekås C, Stang E, Madshus IH.

Mol Cancer Res. 2009 Feb;7(2):275-84. doi: 10.1158/1541-7786.MCR-07-2183.

5.

Hsp90 inhibitor geldanamycin increases the sensitivity of resistant ovarian adenocarcinoma cell line A2780cis to cisplatin.

Solár P, Horváth V, Kleban J, Koval' J, Solárová Z, Kozubík A, Fedorocko P.

Neoplasma. 2007;54(2):127-30.

PMID:
17319785
6.

ErbB2 degradation mediated by the co-chaperone protein CHIP.

Zhou P, Fernandes N, Dodge IL, Reddi AL, Rao N, Safran H, DiPetrillo TA, Wazer DE, Band V, Band H.

J Biol Chem. 2003 Apr 18;278(16):13829-37.

7.

DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90.

Kelland LR, Sharp SY, Rogers PM, Myers TG, Workman P.

J Natl Cancer Inst. 1999 Nov 17;91(22):1940-9.

8.

Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT.

Sain N, Krishnan B, Ormerod MG, De Rienzo A, Liu WM, Kaye SB, Workman P, Jackman AL.

Mol Cancer Ther. 2006 May;5(5):1197-208.

11.
12.
13.

Surface charge and hydrophobicity determine ErbB2 binding to the Hsp90 chaperone complex.

Xu W, Yuan X, Xiang Z, Mimnaugh E, Marcu M, Neckers L.

Nat Struct Mol Biol. 2005 Feb;12(2):120-6.

PMID:
15643424
14.

Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1.

Zsebik B, Citri A, Isola J, Yarden Y, Szöllosi J, Vereb G.

Immunol Lett. 2006 Apr 15;104(1-2):146-55.

PMID:
16384610
17.

KF25706, a novel oxime derivative of radicicol, exhibits in vivo antitumor activity via selective depletion of Hsp90 binding signaling molecules.

Soga S, Neckers LM, Schulte TW, Shiotsu Y, Akasaka K, Narumi H, Agatsuma T, Ikuina Y, Murakata C, Tamaoki T, Akinaga S.

Cancer Res. 1999 Jun 15;59(12):2931-8.

18.

Hsp90, not Grp94, regulates the intracellular trafficking and stability of nascent ErbB2.

Xu W, Mimnaugh EG, Kim JS, Trepel JB, Neckers LM.

Cell Stress Chaperones. 2002 Jan;7(1):91-6.

19.

Contribution of c-erbB-2 and topoisomerase IIalpha to chemoresistance in ovarian cancer.

Hengstler JG, Lange J, Kett A, Dornhöfer N, Meinert R, Arand M, Knapstein PG, Becker R, Oesch F, Tanner B.

Cancer Res. 1999 Jul 1;59(13):3206-14.

20.

Antibiotic radicicol binds to the N-terminal domain of Hsp90 and shares important biologic activities with geldanamycin.

Schulte TW, Akinaga S, Soga S, Sullivan W, Stensgard B, Toft D, Neckers LM.

Cell Stress Chaperones. 1998 Jun;3(2):100-8.

Items per page

Supplemental Content

Support Center